The Hunt for the Next 10 Bagger

[BioSpecialist]

IGXT (MC $54 M) 2 NDA submission + Partnership imminent / Profitable in 2018 /well financed untill profitability expected next year /Lots of BIG News on the way (see below) = 10 Bagger Gem .GL

Upcoming Milestones:

NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July

NDA resubmission for Rizaport (migraine) in early Q3

Start Phase 2a of Montelukast (Alzheimer Disease ) potential Blockbuster

Partnership for Tadalafil could come anytime now

Partnership for Rizaport for EU and USA could also happen anytime now


Monster Pipeline
http://s2.q4cdn.com/790425727/files/design/IntelGenx-Product-Portfolio-and-Pipeline-June-2017.xlsx.jpg


IntelGenx has multi-faceted BD approach for its oral films May 16, 2017
http://www.biotuesdays.com/features/2017/5/11/intelgenx-has-multi-faceted-bd-approach-for-its-oral-films

IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.